A. Z. S. Rohatiner

St Bartholomew's Hospital — United Kingdom

Medicine · Health Sciences

49h-index9.3kcitations154works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(94), Chronic Lymphocytic Leukemia Research(59), Acute Myeloid Leukemia Research(40), Acute Lymphoblastic Leukemia research(35), Viral-associated cancers and disorders(34)

Publications154 total

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up
British Journal of Haematology·2014· 4 citedOpen Access
<sup>90</sup>Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Journal of Clinical Oncology·2013· 203 cited
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Journal of Clinical Oncology·2013· 153 citedOpen Access
Hematologic Malignancy
Elsevier eBooks·2012· 1 cited
Contributors
Elsevier eBooks·2012
Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study
Journal of Clinical Oncology·2011· 212 citedOpen Access
Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies
British Journal of Haematology·2011· 30 cited
Efficacy of an intensive post-induction chemotherapy regimen for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, given predominantly in the out-patient setting
Annals of Hematology·2011· 8 citedOpen Access
90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients
Blood·2010· 16 cited
Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
British Journal of Haematology·2010· 66 citedOpen Access
Follicular lymphoma
2010
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Journal of Clinical Oncology·2010· 330 citedOpen Access
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.
Blood·2009· 29 cited
Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.
Blood·2009
Quantitative PCR Analysis for <i>Bcl-2/IgH</i> in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma
Journal of Clinical Oncology·2009· 38 cited
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin’s Lymphoma: A Review of the Evidence
The Oncologist·2009· 34 cited
Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy
British Journal of Haematology·2009· 1 cited
Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
British Journal of Haematology·2009· 264 cited
Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.
Blood·2008
Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.
Blood·2008· 8 cited
page 1 of 8Next →

Frequent Co-authors

T. Andrew Lister(20), John Radford(13), Tim Lister(13), A. J. Norton(11), James M. Foran(9), Peter Johnson(9), Janet Matthews(7), John Amess(7), David Cunningham(5), J. Amess(5), John Apostolidis(5), D.P. Deakin(5), Andrew Davies(4), David Taussig(4), C. G. A. Price(4), J. Matthews(4), Bryan D. Young(4), Ivana N. Micallef(4), Bertrand Coiffier(3), Christian Gisselbrecht(3)